SEARCH

SEARCH BY CITATION

References

  • 1
    Medicines and Healthcare products Regulatory Agency (MHRA). Healthcare professional reporting: adverse drug reactions. Available at http://yellowcard.mhra.gov.uk/ (last accessed 1 August 2012).
  • 2
    Medicines and Healthcare products Regulatory Agency (MHRA). Safety information. Available at http://yellowcard.mhra.gov.uk/ (last accessed 1 August 2012).
  • 3
    t'Jong GW, Stricker BHC, Choonara I, van den Anker JN. Lack of effect of the European guidance on clinical investigation of medicines in children. Acta Paediatr 2002; 91: 12331238.
  • 4
    Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJM, Aronson JK, Grahame-Smith DG. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol 1996; 42: 423429.
  • 5
    Vallano A, Cereza G, Pedròs C, Agusti A, Danés I, Aguilera C, Arnau JM. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol 2005; 60: 653658.
  • 6
    Hazell L, Shakir SAW. Under reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 385396.
  • 7
    Anderson C, Krska J, Murphy E, Avery A. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Br J Clin Pharmacol 2011; 72: 806822.
  • 8
    Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell L, Krska J, Lee AJ, McLernon DJ, Murphy E, Shakir S, Watson MC. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess 2011; 15: 1234.
  • 9
    Aagaard L, Nielsen L, Hansen E. Consumer reporting of adverse drug reacitons: a retrospective analysis of the Danish adverse drug reactions database from 2004–2006. Drug Saf 2006; 32: 10671074.
  • 10
    McLernon DJ, Bond CM, Hannaford PC, Watson MC, Lee AJ, Hazell L, Avery A. Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals. Drug Saf 2010; 33: 775788.
  • 11
    Tobaiqy M, Stewart D, Helms PJ, Williams J, Crum J, Steer C, McLay J. Parental reporting of adverse drug reactions associated with attention-deficit hyperactivity disorder (ADHD) medications in children attending specialist paediatric clinics in the UK. Drug Saf 2011; 34: 211219.
  • 12
    Blenkinsopp A, Wilkie P, Wang M, Routledge P. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol 2006; 63: 148156.
  • 13
    van Grootheest K, de Jong-van den Berg L. Patients' role in reporting adverse drug reactions. Drug Saf 2004; 3: 363368.
  • 14
    Ekins-Daukes S, Irvine D, Fiddes S. The Yellow Card Scheme: evaluation of patient reporting of suspected adverse drug reactions. Abstract of Eurodrug Conference 2006. Pharmacoepidemiol Drug Saf 2006; 15: S1S316.
  • 15
    Anderson C, Gifford A, Avery A, Fortnum H, Murphy E, Krska J, Bond C. Assessing the usability of methods of public reporting of adverse drug reactions to the UK Yellow Card Scheme. Health Expect 2011. doi: 10.1111/jl.1369-7625.2011.00686.x.
  • 16
    McLernon DJ, Bond CM, Lee AJ, Watson MC, Hannaford PC, Fortnum H, Krska J, Anderson C, Murphy E, Avery A. Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK. Pharmacoepidemiol Drug Saf 2011; 20: 523531.
  • 17
    van Hunsel F, Härmark L, Pal S, Olsson S, van Grootheest K. Experiences with adverse drug reaction reporting by patients: an 11-country survey. Drug Saf 2012; 35: 4560.
  • 18
    European Medicines Agency (EMA). Information on Benefits and Risks of Medicines: Patients' Consumers' and Healthcre Professionals Expectations. London: European Medicines Agency (EMA), 2009.
  • 19
    European Medicines Agency (EMA). The European Medicines Agency Road Map to 2015: The Agency's Contribution to Science, Medicine and Health. London: Eurpean Medicines Agency (EMA), 2010.
  • 20
    Watson R. New rules will allow EU patients to report drug concerns directly. BMJ 2010; 341 (c5344): 689.
  • 21
    Fortnum H, Lee AJ, Rupnik B, Avery A. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain. J Clin Pharm Ther 2011; 37: 161165.
  • 22
    Lorimer S, Cox A, Langford NJ. A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther 2012; 37: 148152.
  • 23
    van Hunsel F, van der Welle C, Passier A, van Puijenbroek E, van Grootheest K. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. Eur J Clin Pharmacol 2010; 66: 11431150.
  • 24
    ‘t Jong GW, Choonara I, Stricker BH, van den Anker JN. Lack of effect of the European guidance on clinical investigation of medicines in children. Clin Pharmacol Ther 2002; 71: 5454.
  • 25
    ‘t Jong GW, Eland IA, Sturkenboom MCJM, van den Anker JN, Stricker BHC. Unlicensed and off label prescription of drugs to children: population based cohort study. BMJ 2002; 324: 13131314.
  • 26
    Ball LK, Evans G, Bostrom A. Risky business: challenges in vaccine risk communication. Pediatrics 1998; 101: 453458.
  • 27
    Bellaby P. Communication and miscommunication of risk: understanding UK parents' attitudes to combined MMR vaccination. BMJ 2003; 327: 725728.
  • 28
    Casiday RE, Cox AR. Restoring confidence in vaccines by explaining vaccine safety monitoring – is a targeted approach needed? Drug Saf 2006; 29: 11051109.
  • 29
    Mills E, Jadad AR, Ross C, Wilson K. Systematic review of qualitative studies exploring parental beliefs and attitudes toward childhood vaccination identifies common barriers to vaccination. J Clin Epidemiol 2005; 58: 10811088.
  • 30
    Mukattash TL, Millership JS, Collier PS, McElnay JC. Public awareness and views on unlicensed use of medicines in children. Br J Clin Pharmacol 2008; 66: 838845.
  • 31
    Gust D, Darling N, Kennedy A, Schwartz B. Parents with doubts about vaccines: which vaccines and reasons why. Pediatrics 2008; 122: 718725.
  • 32
    Hobson-West P. Understanding vaccination resistance: moving beyond risk. Health Risk Soc 2003; 5: 273283.
  • 33
    Grinyer A. Young adults with cancer: parents' interactions with health care professionals. Eur J Cancer Care (Engl) 2004; 13: 8895.
  • 34
    Kai J. What worries parents when their preschool children are acutely ill, and why: a qualitative study. BMJ 1996; 313: 983986.
  • 35
    Tobaiqy M, Stewart D, Helms PJ, Bond MC, Lee AJ, McLay J. Views of parents and pharmacists following participation in a paediatric pharmacovigialnce study. Pharm World Sci 2010; 32: 334338.
  • 36
    Patton M. Qualitative Research and Evaluation Methods. London: Sage Publications, 2002.
  • 37
    ADRIC. Adverse drug reactions in children. Available at http://www.adric.org.uk/Index.html (last accessed 12 March 2012).
  • 38
    Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 12551259.
  • 39
    Boeije H. Analysis in Qualitative Research. London: Sage Publications Ltd, 2010.
  • 40
    Bryman A, Burgess R. Analyzing Qualitative Data. London: Routledge, 2004.
  • 41
    Strauss A, Corbin C. Basics of Qualitative Research. London: Thousand Oaks, CA Sage Publictions Ltd, 1998.
  • 42
    Charmaz K. Grounded theory. Objectivist and constructivist methods. In: Strategies of Qualitative Inquiry, eds Denzin NK , Lincoln YS . London: Sage Publications, 2003; 249291.
  • 43
    Sturges J, Hanrahan K. Comparing telephone and face-to-face qualitative interviewing: a research note. Qual Res 2004; 4: 107118.